International Journal of Clinical Case Reports 2024, Vol.14, No.3, 167-177 http://medscipublisher.com/index.php/ijccr 177 Rameshbabu S., Labadie B., Argulian A., and Patnaik A., 2021, Targeting innate immunity in cancer therapy, Vaccines, 9(2): 138. https://doi.org/10.3390/vaccines9020138 PMid:33572196 PMCid:PMC7916062 Retecki K., Seweryn M., Graczyk-Jarzynka A., and Bajor M., 2021, The immune landscape of breast cancer: strategies for overcoming immunotherapy resistance, Cancers, 13(23): 6012. https://doi.org/10.3390/cancers13236012 PMid:34885122 PMCid:PMC8657247 Schepisi G., Gianni C., Palleschi M., Bleve S., Casadei C., Lolli C., Ridolfi L., Martinelli G., and Giorgi U., 2023, The new frontier of immunotherapy: chimeric antigen receptor T (CAR-T) cell and macrophage (CAR-M) therapy against breast cancer, Cancers, 15(5): 1597. https://doi.org/10.3390/cancers15051597 PMid:36900394 PMCid:PMC10000829 Shi T., Song X., Wang Y., Liu F., and Wei J., 2020, Combining oncolytic viruses with cancer immunotherapy: establishing a new generation of cancer treatment, Frontiers in Immunology, 11: 683. https://doi.org/10.3389/fimmu.2020.00683 PMid:32411132 PMCid:PMC7198760 Sivaganesh V., Promi N., Maher S., and Peethambaran B., 2021, Emerging immunotherapies against novel molecular targets in breast cancer, International Journal of Molecular Sciences, 22(5): 2433. https://doi.org/10.3390/ijms22052433 PMid:33670942 PMCid:PMC7957700 Venetis K., Invernizzi M., Sajjadi E., Curigliano G., and Fusco N., 2020, Cellular immunotherapy in breast cancer: the quest for consistent biomarkers, Cancer Treatment Reviews, 90: 102089. https://doi.org/10.1016/j.ctrv.2020.102089 PMid:32889360 Wang J., and Zhou P., 2017, New approaches in CAR-T cell immunotherapy for breast cancer, Advances in Experimental Medicine and Biology, 1026: 371-381. https://doi.org/10.1007/978-981-10-6020-5_17 PMid:29282693 Whiteside T., Demaria S., Rodriguez-Ruiz M., Zarour H., and Melero I., 2016, Emerging opportunities and challenges in cancer immunotherapy, Clinical Cancer Research, 22: 1845-1855. https://doi.org/10.1158/1078-0432.CCR-16-0049 PMid:27084738 PMCid:PMC4943317 Zacharakis N., Chinnasamy H., Black M., Xu H., Lu Y., Zheng Z., Pasetto A., Langhan M., Shelton T., Prickett T., Gartner J., Jia L., Trebska-Mcgowan K., Somerville R., Robbins P., Rosenberg S., Goff S., and Feldman S., 2018, Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer, Nature Medicine, 24: 724-730. https://doi.org/10.1038/s41591-018-0040-8 PMid:29867227 PMCid:PMC6348479 Zhang Y., and Zhang Z., 2020, The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications, Cellular and Molecular Immunology, 17: 807-821. https://doi.org/10.1038/s41423-020-0488-6 PMid:32612154 PMCid:PMC7395159 Zhao X., Dong F., Chen W., and Liu C., 2023, Immunotherapy in combination with neoadjuvant anthracycline‑free chemotherapy for triple‑negative early breast cancer: a case report, Oncology Letters, 26(3): 374. https://doi.org/10.3892/ol.2023.13961 PMid:37559578 PMCid:PMC10407723
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==